Bibliography
1.
Meyer B. FDA "Black Box"
Labeling. Ann Emerg Med. 2003 Apr; 41(4):55960
2.
Lischke V, et al. Droperidol causes a dose-dependent
prolongation of the QT interval. Anesth Analg. 1994; 79:983-986
3.
Guy JM, et al. Torsades de pointes et
allongement de la duree de l'intervalle QT apres injection de droperidol. An de
Cardiologie et d'Angeiolie. 1991; 40:541-545
4.
Reilly et al. QTc-interval
abnormalities and psychotropic drug therapy in psychiatric patients. Lancet
2000; 355:1048--52
5.
Lawrence & Nasraway, Pharmacotherapy
1997; 17(3): 531-7
6.
Frye et al. Continuous droperidol infusion for
management of agitated delirium in an intensive care unit. Psychosomatics
1995; 36:301-5
7.
Drolet
B et al. Droperidol lengthens cardiac repolarization due to block of the rapid component
of the delayed rectifier potassium current. J Cardiovas Electrophys 1999;
10(12):1597--604
8.
Michalets
et a. Torsade de pointes resulting from the addition
of droperidol to an existing cytochrome P450 drug interaction. Ann Pharmacother
1998; 32(7-8):761-5
9.
Faigel
et al. Torsade de pointes complicating the treatment of bleeding esophageal
varices: association with neuroleptics, vasopressin, and electrolyte imbalance.
Am J Gastroenterol 1995; 90(5):822-4
10. Roden D. Acquired long QT syndromes
and the risk of proarrhythmia. J Cardiovasc Electrophys 2000; 11:938-40
11. Fenichel RR. Development of drugs
that alter ventricular repolarization. Am J Ther 2002; 9(2):127-39
12. Malik M and Camm AJ. Evaluation of
drug-induced QT interval prolongation. Drug Safety 2001; 24(5):323-351
13. Curran ME et al. Molecular mechanism
of a serious adverse drug reaction: drug induced cardiac arrhythmias. Pharm
Disc Development, 2002/03
14.